Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year-ended December 31, 2013.
Raj Rai, Chief Executive Officer commented, “2013 was a pivotal year for Akorn. As a result of investment in our sales…
Akorn’s consolidated revenue for fourth quarter 2013 increases 19% to $85 million
No comments:
Post a Comment